Business
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
LOS ANGELES, February 17, 2026--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company’s lead investigational therapy,
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"Dr. Robert Redfield","displaySize":"","headline":null,"caption":"Dr. Robert Redfield","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":293,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/ff68fdc1574ecc5c963af7079ecae5f9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/13cEL1cTGmfB5jQez8iZqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ff68fdc1574ecc5c963af7079ecae5f9","width":293,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1435,"height":482,"url":"https://media.zenfs.com/en/business-wire.com/f7724974ba35a76a632a84cbd7757ab3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hlg4Mp9I4d6wCFpYjw1mSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f7724974ba35a76a632a84cbd7757ab3","width":960,"height":322},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XyNIuRYsUhW1CRP.pSmtdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f7724974ba35a76a632a84cbd7757ab3","width":1200,"height":403}}},{"type":"text","content":"Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company’s lead investigational therapy","length":168,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, February 17, 2026--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company’s lead investigational therapy, GX-03, which is currently in Phase 2 clinical trials.","length":571,"tagName":"p"},{"type":"text","content":""Dr. Redfield brings an incomparable level of experience, public health insight, and regulatory knowledge to the Turn ecosystem," said Brad Burnam, Chief Executive Officer of Turn Therapeutics. "As we advance GX-03 t...